| Literature DB >> 28679953 |
Changrong Ge1, Dongmei Tong1,2, Bibo Liang1,2, Erik Lönnblom1, Nadine Schneider3, Cecilia Hagert4, Johan Viljanen5, Burcu Ayoglu6, Roma Stawikowska7, Peter Nilsson6, Gregg B Fields7, Thomas Skogh8, Alf Kastbom8, Jan Kihlberg5, Harald Burkhardt3, Doreen Dobritzsch9, Rikard Holmdahl1,4,10.
Abstract
Today, it is known that autoimmune diseases start a long time before clinical symptoms appear. Anti-citrullinated protein antibodies (ACPAs) appear many years before the clinical onset of rheumatoid arthritis (RA). However, it is still unclear if and how ACPAs are arthritogenic. To better understand the molecular basis of pathogenicity of ACPAs, we investigated autoantibodies reactive against the C1 epitope of collagen type II (CII) and its citrullinated variants. We found that these antibodies are commonly occurring in RA. A mAb (ACC1) against citrullinated C1 was found to cross-react with several noncitrullinated epitopes on native CII, causing proteoglycan depletion of cartilage and severe arthritis in mice. Structural studies by X-ray crystallography showed that such recognition is governed by a shared structural motif "RG-TG" within all the epitopes, including electrostatic potential-controlled citrulline specificity. Overall, we have demonstrated a molecular mechanism that explains how ACPAs trigger arthritis.Entities:
Keywords: Autoimmunity; Immunology
Year: 2017 PMID: 28679953 PMCID: PMC5499374 DOI: 10.1172/jci.insight.93688
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708